Gundugurti PR, et al. – This cross–sectional, survey–based study aimed to establish psychiatrists’ perspective on the impact of long–acting injectables (LAIs) antipsychotics on the socio–economic and functional burden of schizophrenia. Regardless of enhanced treatment adherence and potential to lower risk of rehospitalizations from relapse, LAIs are not the preferred treatment choice for patients with schizophrenia in India, owing to their perceived high costs.